DTIL
Precision BioSciences, Inc.
There isn't enough reported data to score DTIL yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DTIL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
DTIL's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DTIL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $7.23 | -10% |
| Current | 24x | $8.04 | — |
| Fair | 31x | $10.17 | +26% |
| Expensive | 35x | $11.52 | +43% |
Historical ranges are pointers, not guarantees.
DTIL's PE is 24x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DTIL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect DTIL's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DTIL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.33 | +$9.59 |
| Q2 2026 | -$1.23 | +$8.44 |
| Q1 2026 | -$2.10 | +$0.77 |
| Q4 2025 | -$3.56 | -442% |
| Q3 2025 | -$9.26 | -5888% |
| Q2 2025 | -$9.67 | -3219% |
| Q1 2025 | -$2.87 | +$4.49 |
| Q4 2024 | $1.04 | +$17.00 |
DTIL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DTIL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $10.8M | +37272% |
| Q4 2025 | $34.2M | +5261% |
| Q3 2025 | $13K | -98% |
| Q2 2025 | $18K | -100% |
| Q1 2025 | $29K | -100% |
| Q4 2024 | $638K | -91% |
| Q3 2024 | $576K | -96% |
| Q2 2024 | $49.9M | +152% |
DTIL's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -84% | +76165 points |
| Q4 2025 | 37% | +3931 points |
| Q3 2025 | -158977% | -155283 points |
| Q2 2025 | -121539% | -121587 points |
| Q1 2025 | -76248% | -76225 points |
| Q4 2024 | -3894% | -3683 points |
| Q3 2024 | -3694% | -3599 points |
| Q2 2024 | 48% | +109 points |
DTIL's operating margin was −84% last quarter, up 76165 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DTIL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DTIL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.1M | +$138K |
| Q2 2026 | -$13.4M | +$6.8M |
| Q1 2026 | -$12M | +$7.2M |
| Q4 2025 | -$11.3M | +$7.5M |
| Q3 2025 | -$15.3M | -$9.3M |
| Q2 2025 | -$20.3M | -$5.4M |
| Q1 2025 | -$19.1M | -$49K |
| Q4 2024 | -$18.8M | -$10.4M |
DTIL has burned cash in almost every quarter: −$52M over the past year, against −$73M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DTIL on cash generation, producing positive trailing cash flow while its opponent burns cash.
DTIL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.1% | +1.6M shares |
| 1 year | +148% | +16.4M shares |
| 3 years | +642% | +23.7M shares |
| 5 years | +1472% | +25.7M shares |
DTIL has 27M diluted shares, up 148% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DTIL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DTIL Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DTIL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 55.4 | Neutral |
DTIL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DTIL PE vs Healthcare Sector
| Metric | DTIL | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 17 | 29 | 12 pts below |
DTIL is trading at 24x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DTIL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% above |
| 20 week MA | $7.47 | 7.6% above |
| 50 week MA | $6.35 | 27% above |
| 100 week MA | $5.75 | 40% above |
| 200 week MA | $10.3 | 22% below |
DTIL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DTIL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $421.5 | $280.5 | -33% |
| 2021 | $280.5 | $254.1 | -9.4% |
| 2022 | $254.1 | $30.3 | -88% |
| 2023 | $30.3 | $11.0 | -64% |
| 2024 | $11.0 | $4.65 | -58% |
| 2025 | $4.65 | $4.23 | -9% |
| 2026 YTD | $4.23 | $8.04 | +90% |
DTIL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.